What Will Top 10 Cancer Drugs Market Be Like In Upcoming 5 Y...| MENAFN.COM

Friday, 07 October 2022 03:20 GMT

What Will Top 10 Cancer Drugs Market Be Like In Upcoming 5 Years?


(MENAFN- EIN Presswire)

The global top 10 cancer drugs industry generated $63.61 billion in 2018, and is estimated to reach $129.94 billion by 2026, witnessing a CAGR of 9.8%.

PORTLAND, OREGON, UNITED STATES, August 18, 2022 /EINPresswire.com / -- Allied Market Research published a report, titled, 'Top 10 Cancer Drugs Market by Region (Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2018–2026.' According to the report, the global top 10 cancer drugs industry generated $63.61 billion in 2018, and is estimated to reach $129.94 billion by 2026, witnessing a CAGR of 9.8% from 2019 to 2026.

Request Sample Report At:

Cancer caused when the cells present in the body grow at an uncontrolled rate leading to the formation of a tumor. Cancer has different stages based on its progression. Metastasis is the final stage of the disease, which is marked by the invasion of tumor into others parts of body. The management of cancer in patients requires the use of different forms of drugs such as hormonal therapy, immunotherapy, targeted therapy, and others.

Drugs such as Revlimid, Opdivo, Keytruda, Herceptin, Avastin, Rituxan, Imbruvica, Neulasta/Peglasta, Ibrance, and Zytiga are the top selling drugs in 2018. The key drivers of the global cancer drugs market are increase in incidence of cancer, rise in adoption of advance therapies such as biological & targeted drug therapies, surge in geriatric population, and rise in collaborations & partnerships to facilitate drug development. In addition, availability of the drugs and increase in healthcare expenditure have significantly contributed toward the growth of this market. Increase in number of pipeline drugs along with high potential of emerging economies are further expected to provide lucrative opportunities for market expansion. However, high cost involved in new drug development and adverse effects related to cancer drugs are expected to impede the market growth.

Table Of Content:

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2018
3.4. Porter's five forces analysis
3.5. Market dynamics

For Purchase Inquiry of Top 10 Cancer Drugs Market Report:

Drivers, restraints, and opportunities

Surge in incidence of cancer across the globe, increase in aging population, and rise in expenditure of government on healthcare infrastructure drive the global top 10 cancer drugs market. However, adverse effects related to usage of cancer usage hinder the market growth. Contrarily, surge in number of pipeline drugs and untapped potential in emerging geographies create new opportunities in the market.

Leading market players

AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Johnson & Johnson (Janssen Global Services, LLC)
Merck & Co., Inc.
Novartis AG
Pfizer Inc.

Browse Trending Related Reports Here:

Medical Spa Market:

Hemodialysis Market:

Allergy Treatment Market:

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of 'Market Research Reports' and 'Business Intelligence Solutions.' AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

MENAFN18082022003118003196ID1104718901


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.